RSS feed

Publications (original articles or review articles) published in 2022 from OUS - NKRG

13 publications found

Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, Christensen IE, Kro GB, Kvien TK, Jahnsen J, Munthe LA, Chopra A, Warren DJ, Mjaaland S, Haavardsholm EA, Grødeland G, Provan SA, Vaage JT, Syversen SW, Goll GL, Jørgensen KK (2022)
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
Lancet Rheumatol, 5 (1), e36-e46
DOI 10.1016/S2665-9913(22)00330-7, PubMed 36415604

Christensen IE, Jyssum I, Tveter AT, Sexton J, Tran TT, Mjaaland S, Kro GB, Kvien TK, Warren DJ, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Grødeland G, Lund-Johansen F, Jørgensen KK, Syversen SW, Goll GL, Provan SA (2022)
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study
BMC Med, 20 (1), 378
DOI 10.1186/s12916-022-02587-8, PubMed 36199139

Ibsen JH, Chopra A, Vaage EB, Vaage JT, Lund-Johansen F, Lundin KEA (2022)
Immune responses to SARS-CoV-2 vaccines in celiac disease
Scand J Gastroenterol, 58 (2), 142-147
DOI 10.1080/00365521.2022.2114809, PubMed 36049123

Kared H, Wolf AS, Alirezaylavasani A, Ravussin A, Solum G, Tran TT, Lund-Johansen F, Vaage JT, Nissen-Meyer LS, Nygaard UC, Hungnes O, Robertson AH, Næss LM, Trogstad L, Magnus P, Munthe LA, Mjaaland S (2022)
Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
Nat Commun, 13 (1), 4165
DOI 10.1038/s41467-022-31888-y, PubMed 35851055

König M, Torgauten HM, Tran TT, Holmøy T, Vaage JT, Lund-Johansen F, Nygaard GO (2022)
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
JAMA Neurol, 79 (3), 307-309
DOI 10.1001/jamaneurol.2021.5109, PubMed 35072702

Nissen-Meyer LSH, Czapp E, Naper C, Jensen T, Boulland LML (2022)
Screening for antibodies to HLA class I in apheresis donors following Covid-19 or SARS-CoV-2 vaccination
Transfus Apher Sci, 61 (5), 103567
DOI 10.1016/j.transci.2022.103567, PubMed 36089469

Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic-Sarac M, Hestdalen ML, Brodin E, Rustad EH, Dai KZ, Vaage JT, Nissen-Meyer LSH, Sund F, Wader KF, Bjornevik AT, Meyer PA, Nygaard GO, König M, Smeland S, Lund-Johansen F, Olweus J, Kolstad A (2022)
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination
Br J Haematol, 197 (6), 697-708
DOI 10.1111/bjh.18149, PubMed 35254660

Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, Bjørlykke KH, Mjaaland S, Warren DJ, Kvien TK, Chopra A, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Jørgensen KK, Goll GL (2022)
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
RMD Open, 8 (2)
DOI 10.1136/rmdopen-2022-002417, PubMed 36328399

Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, Mjaaland S, Warren DJ, Kvien TK, Grødeland G, Nissen-Meyer LSH, Ricanek P, Chopra A, Andersson AM, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Lund-Johansen F, Jørgensen KK, Goll GL (2022)
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy
Arthritis Rheumatol, 74 (8), 1321-1332
DOI 10.1002/art.42153, PubMed 35507355

Søraas A, Grødeland G, Granerud BK, Ueland T, Lind A, Fevang B, Murphy SL, Huse C, Nygaard AB, Steffensen AK, Al-Baldawi H, Holberg-Petersen M, Andresen LL, Ågnes C, Ranheim T, Schanke Y, Istre M, Dahl JA, Chopra A, Dudman S, Kaarbø M, Andersen JT, Vaage EB, Tran TT, Vaage JT et al. (2022)
Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
Front Immunol, 13, 964525
DOI 10.3389/fimmu.2022.964525, PubMed 36159859

Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K et al. (2022)
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
NPJ Vaccines, 7 (1), 174
DOI 10.1038/s41541-022-00586-7, PubMed 36585405

Tunheim G, Rø GØI, Chopra A, Aase A, Kran AB, Vaage JT, Lund-Johansen F, Hungnes O (2022)
Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021
Influenza Other Respir Viruses, 16 (6), 1004-1013
DOI 10.1111/irv.13024, PubMed 35770841

Weinreich I, Bengtsson M, Lauronen J, Naper C, Lokk K, Helanterä I, Andrésdóttir MB, Sørensen SS, Wennberg L, Reisaeter AV, Møller B, Koefoed-Nielsen P (2022)
Scandiatransplant acceptable mismatch program-10 years with an effective strategy for transplanting highly sensitized patients
Am J Transplant, 22 (12), 2869-2879
DOI 10.1111/ajt.17182, PubMed 36030513